论文信息 - Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. - 字舞流文

Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma.

W. Linehan | R. Srinivasan | W. Rathmell | E. Jonasch | J. Maranchie | S. Welsh | S. Oudard | V. Narayan | O. Iliopoulos | F. Donskov | R. Perini | T. Else | S. Thamake | B. Maughan | N. Zojwalla | E. Park